Value
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.4 |
| P/S | 4.5 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 4.0 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 30.0x
- ▸PEG: 0.10
VCYT · Why this verdict
Why Veracyte (VCYT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Veracyte has beaten earnings expectations in all four of the most recent quarters, with individual surprises ranging from 29% to 60%, suggesting its genomic diagnostic tests for cancer recurrence risk are generating revenue at a pace consistently ahead of analyst models. Earnings | Veracyte beats quarterly earnings per share estimates by at least 10% in at least 3 of the next 4 quarters, sustaining the execution record. | →Stable |
| CounterThe beat streak may partly reflect overly conservative guidance from management rather than fundamental outperformance; if management updates guidance more aggressively, future beats could be smaller or absent even if the underlying business grows on plan. | ||
Veracyte achieves a Rule of 40 score of 41, combining 22% revenue growth with improving operating profitability, placing it in the upper tier of diagnostics companies for capital efficiency relative to growth rate. Quality breakdown | Revenue growth remains above 18% year-over-year and the Rule of 40 score stays at or above 35 over the next four quarters. | →Stable |
| CounterWith a net margin still at 16% and operating margin that has not yet compounded to durable levels, any growth deceleration caused by reimbursement headwinds or test adoption slowdowns could push the Rule of 40 score below 30 quickly. | ||
Veracyte's revenue is heavily concentrated in its Decipher Prostate and Afirma tests while relying on sole-source suppliers for the reagents and equipment used to run those tests, creating two interlocking single points of failure in the business model. Bear case | Neither a product reimbursement cut nor a supplier disruption is announced in the next 12 months, and revenue concentration in the two lead products does not increase beyond current levels. | →Stable |
| CounterBoth the Decipher Prostate and Afirma tests benefit from strong clinical evidence bodies and established reimbursement codes, which create durable demand that is less vulnerable to competition than commodity diagnostics products. | ||
The analyst consensus price target has been reached, leaving a negative implied upside of 13.1%, and the momentum score of 3.9 combined with falling on-balance volume confirms that price pressure is currently to the downside despite the strong operating track record. Warnings | Analyst consensus target is revised upward to at least $55 within 12 months, restoring a positive price target gap; alternatively RSI rises above 55 signaling technical recovery. | →Stable |
| CounterAnalyst target revisions often lag earnings beats by one to two quarters; if Veracyte delivers another strong beat cycle, targets may be revised upward promptly, creating an attractive re-entry window at the current price. | ||
Veracyte has beaten earnings expectations in all four of the most recent quarters, with individual surprises ranging from 29% to 60%, suggesting its genomic diagnostic tests for cancer recurrence risk are generating revenue at a pace consistently ahead of analyst models.
→StableEarnings
- Expectation
- Veracyte beats quarterly earnings per share estimates by at least 10% in at least 3 of the next 4 quarters, sustaining the execution record.
CounterThe beat streak may partly reflect overly conservative guidance from management rather than fundamental outperformance; if management updates guidance more aggressively, future beats could be smaller or absent even if the underlying business grows on plan.
Veracyte achieves a Rule of 40 score of 41, combining 22% revenue growth with improving operating profitability, placing it in the upper tier of diagnostics companies for capital efficiency relative to growth rate.
→StableQuality breakdown
- Expectation
- Revenue growth remains above 18% year-over-year and the Rule of 40 score stays at or above 35 over the next four quarters.
CounterWith a net margin still at 16% and operating margin that has not yet compounded to durable levels, any growth deceleration caused by reimbursement headwinds or test adoption slowdowns could push the Rule of 40 score below 30 quickly.
Veracyte's revenue is heavily concentrated in its Decipher Prostate and Afirma tests while relying on sole-source suppliers for the reagents and equipment used to run those tests, creating two interlocking single points of failure in the business model.
→StableBear case
- Expectation
- Neither a product reimbursement cut nor a supplier disruption is announced in the next 12 months, and revenue concentration in the two lead products does not increase beyond current levels.
CounterBoth the Decipher Prostate and Afirma tests benefit from strong clinical evidence bodies and established reimbursement codes, which create durable demand that is less vulnerable to competition than commodity diagnostics products.
The analyst consensus price target has been reached, leaving a negative implied upside of 13.1%, and the momentum score of 3.9 combined with falling on-balance volume confirms that price pressure is currently to the downside despite the strong operating track record.
→StableWarnings
- Expectation
- Analyst consensus target is revised upward to at least $55 within 12 months, restoring a positive price target gap; alternatively RSI rises above 55 signaling technical recovery.
CounterAnalyst target revisions often lag earnings beats by one to two quarters; if Veracyte delivers another strong beat cycle, targets may be revised upward promptly, creating an attractive re-entry window at the current price.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Veracyte has posted four consecutive earnings beats averaging 48% upside surprise with 22% revenue growth and a Rule of 40 score of 41, but negative price momentum and an analyst target that has already been reached create an unfavorable near-term risk profile.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.3 |
| ROA | 2.5 |
| Gross margin | 10.0 |
| Op margin | 6.5 |
| Net margin | 8.1 |
| Current ratio | 5.0 |
| FCF quality | 7.9 |
| Moat | 6.4 |
| Rule of 40 | 7.1 |
| Piotroski F | 8.9 |
- ▸Strong margins: 16%
- ▸Rule of 40: 41 (pass)
- ▸Strong Piotroski F-Score: 8/9
Growth
8.9/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 7.9 |
| EPS growth | 10.0 |
- ▸Strong growth: 22% YoY
Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.7 |
- ▸Overbought (RSI 74)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 9.0 |
| Analyst rating | 7.0 |
| Price target | 3.4 |
- ▸LLM news sentiment: +0.80 (n=1)
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Below analyst target
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $10,079,635 (0.221% of mkt cap)
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.3 |
| quality rank | 6.7 |
| growth rank | 6.9 |
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.9 |
| support resistance | 2.6 |
| 52w position | 8.7 |
Risk (lower is worse)
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 3.5 |
| volatility | 0.4 |
| put call | 5.3 |
| implied vol | 1.8 |
| beta | 3.6 |
| debt equity | 2.1 |
- ▸High IV: 69%
- ▸Concentration risks: 2 HIGH, 2 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Extreme risk factors.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:5.2>=4.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.80
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.5=NEGATIVE
Warning (2)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.53
Upside
-22.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 1.93>1.3, MCap $4.6B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 8.9 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-1.5=NEGATIVE.
The strongest dimensions are Growth at 8.9, Catalyst at 7.0, and Sentiment at 6.6; the weakest are Risk (lower is worse) at 2.9, Insider at 3.4, and Value at 4.3. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -1.53 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Streak Genomic Dx
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, breaking the consecutive beat streak.
- P2Rule Of 40 Growth Profile
Trip ifRevenue growth falls below 12% year-over-year for 2 consecutive quarters, pushing the Rule of 40 score below 28.
- P3Product Supplier Dual Concentration
Trip ifA reimbursement rate cut of more than 10% is announced for either the Decipher Prostate or Afirma test, reducing revenue guidance by more than 5%.
- P4Target Reached Momentum Headwind
Trip ifStock price drops below $40, more than 18% below the current $49.15, with momentum score staying below 3.5 for more than 3 months.